Literature DB >> 992711

Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.

M R Daha, D T Fearon, K F Austen.   

Abstract

C3 nephritic factor (C3NeF) interacts with native C3 and B in the absence of D to generate a C3 convertase containing an uncleaved form of B. Dose response studies with C3NeF and B, respectively, revealed incremental C3 inactivation without loss of B. These findings are in agreement with the previous isolation from such reaction mixtures of a 10S complex containing haemolytically inactive C3 and active B and manifesting C3 convertase activity. Functional contamination of C3 with C3b was negated by demonstrating that pretreatment of C3 with C3bINA had no effect on its subsequent interaction with B and C3NeF to generate C3 convertase activity, while pretreatment of C3b eliminated its effective interaction with B and C3NeF. Relatively higher concentrations of C3bINA present during interaction of C3, B and C3NeF suppressed C3 inactivation, indicating its dependence on amplification by utilization of the initial C3b generated. Trace quantities of D were not found by functional analyses of C3, B and C3NeF and pretreatment of these proteins with a concentration of DFP sufficient to suppress D activity had no effect on their effective interaction. The introduction of D to mixtures of C3NeF, B, and C3 resulted in B clevage and more efficient expression of C3 convertase function as defined by a reduced requirement for C3NeF.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 992711      PMCID: PMC1445153     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.

Authors:  W Vogt; G Schmidt; L Dieminger; R Lynen
Journal:  Z Immunitatsforsch Exp Klin Immunol       Date:  1975-07

2.  The properdin system and immunity. XIII. Assay and properties of a heat-labile serum factor (factor B) in the properdin system.

Authors:  L BLUM; L PILLEMER; I H LEPOW
Journal:  Z Immun exp ther       Date:  1959 Oct-Nov

3.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

4.  Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF).

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

7.  Properdin: initiation of alternative complement pathway.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

8.  Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.

Authors:  R D Schreiber; R G Medicus; O Gïtze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

9.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  4 in total

Review 1.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

2.  Modulation of the formation of the human amplification C3 convertase of complement by polycations.

Authors:  F Maillet; M D Kazatchkine
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

3.  Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series.

Authors:  Giuseppina Spartà; Ariana Gaspert; Thomas J Neuhaus; Marcus Weitz; Nilufar Mohebbi; Urs Odermatt; Peter F Zipfel; Carsten Bergmann; Guido F Laube
Journal:  Clin Kidney J       Date:  2018-02-28

Review 4.  A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.

Authors:  Francesco Paolo Schena; Pasquale Esposito; Michele Rossini
Journal:  Int J Mol Sci       Date:  2020-01-14       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.